Prelude Capital Management, LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $564,030 - $794,970	-9,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $988,976 - $1.39 Million	-11,300 Reduced 55.67%	9,000 $788,000
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $1.79 Million - $2.19 Million	20,300 New	20,300 $2 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $2.05 Million - $2.51 Million	-17,900 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $1.3 Million - $2.12 Million	17,900	17,900 $2.1 Million

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.